Enhancement of gemcitabine efficacy by K73-03 via epigenetically regulation of miR-421/SPINK1 in gemcitabine resistant pancreatic cancer cells

Shopit, Abdullah; Li, Xiaodong; Wang, Shisheng; Awsh, Mohammed; Safi, Mohammed; Chu, Peng; Jia, Jianlong; Alradhi, Mohammed; Baldi, Salem; Wang, Fuhan; Fang, Jun; Peng, Jinyong; Ma, Xiaodong; Tang, Zeyao; Shu, Xiaohong

doi:10.1016/j.phymed.2021.153711

Cited by 6 publications

(6 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MiR-21 regulates cisplatin resistance of GC cells through the PI3K/Akt/mTOR pathway [63] . MiR-421 was involved in regulating 5-fluorouracil and gemcitabine resistance in MGC-803 GC cell lines and pancreatic cancer cell lines [64,65] . The sensitivity of GC cells to cisplatin and trastuzumab was regulated by miR-223/FBXW7 axis [66,67] .…”

Section: Discussionmentioning

confidence: 99%

“…[ 63 ] MiR-421 was involved in regulating 5-fluorouracil and gemcitabine resistance in MGC-803 GC cell lines and pancreatic cancer cell lines. [ 64 , 65 ] The sensitivity of GC cells to cisplatin and trastuzumab was regulated by miR-223/FBXW7 axis. [ 66 , 67 ] Therefore, the purpose of this study was to compare the diagnostic value of these 4 miRNAs in GC.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical role of miR-421 as a novel biomarker in diagnosis of gastric cancer patients

Wang

et al. 2022

Medicine

View full text Add to dashboard Cite

Background: Gastric cancer (GC) has been identified as one of the most common malignancies. It was found that microRNAs can be used as potential biomarkers for GC diagnosis. The aim of this study was to estimate the diagnostic value of 4 potential microRNAs in GC.Methods: PubMed, Embase, Cochrane Library, and Web of Science were used to search published studies. The quality of the studies was scored with the Quality Assessment of Diagnostic Accuracy Studies. The pooled sensitivity and specificity, diagnostic odds ratio (DOR) and area under the curve (AUC) were calculated. The heterogeneity was evaluated using Cochrane Q statistics and the inconsistency index.Results: A total of 22 studies reporting the diagnostic value of miR-21 (n = 9), miR-106 (n = 10), miR-421 (n = 5) and miR-223 (n = 3) were included. Quality Assessment of Diagnostic Accuracy Studies scores showed the high quality of the selected 22 articles. The random effects model was adopted by evaluating the heterogeneity between articles. The DOR, AUC, and Q value of miRNA-21 were 12.37 (95% confidence interval [CI]: 5.36-28.54), 0.86 and 0.79, respectively. The DOR, AUC and Q value of miRNA-106 were 12.98 [95% CI: 7.14-23.61], 0.85 and 0.78, respectively. The DOR, AUC and Q value of miRNA-421 were 27.86 [95% CI: 6.04-128.48], 0.92 and 0.86, respectively. The DOR, AUC and Q value of miRNA-223 were 18.50 [95% CI: 7.80-43.86], 0.87 and 0.80, respectively. These results indicate that miRNA-421 has the highest diagnostic accuracy, followed by miR-223, miRNA-21, and miRNA-106 among the 4 microRNAs in GC.Conclusions: miR-21, miR-106, miR-421, and miR-223 have good diagnostic efficacy, especially miR-421, could be used as auxiliary diagnostic indicator for GC.Abbreviations: AUC = area under the curve, CI = confidence interval, DOR = diagnostic odds ratio, GC = gastric cancer, ROC = receiver operating characteristic.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Clinical role of miR-421 as a novel biomarker in diagnosis of gastric cancer patients

Wang

et al. 2022

Medicine

View full text Add to dashboard Cite

show abstract

“…The expression pattern of microRNAs (miRNAs) can be used as a tool for cancer diagnosis and prognosis, and miRNAs play a role in almost all aspects of tumor biology, including proliferation, apoptosis, invasion, metastasis, and angiogenesis (40). SPINK1 overexpression enhances resistance to gemcitabine (GCB) (a first-line chemotherapy drug for pancreatic cancer) (41). The oleanolic acid (OA) derivative K73-03 reverses SPINK1-mediated GCB resistance by downregulating miR-421 (41).…”

Section: Spink1 Is Regulated By Mirnamentioning

confidence: 99%

“…SPINK1 overexpression enhances resistance to gemcitabine (GCB) (a first-line chemotherapy drug for pancreatic cancer) (41). The oleanolic acid (OA) derivative K73-03 reverses SPINK1-mediated GCB resistance by downregulating miR-421 (41). miR-421 is a tumor-promoting factor (42)(43)(44).…”

Section: Spink1 Is Regulated By Mirnamentioning

confidence: 99%

See 1 more Smart Citation

SPINKs in Tumors: Potential Therapeutic Targets

Liao

Wang

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

The serine protease inhibitor Kazal type (SPINK) family includes SPINK1-14 and is the largest branch in the serine protease inhibitor family. SPINKs play an important role in pancreatic physiology and disease, sperm maturation and capacitation, Nager syndrome, inflammation and the skin barrier. Evidence shows that the unregulated expression of SPINK1, 2, 4, 5, 6, 7, and 13 is closely related to human tumors. Different SPINKs exhibit various regulatory modes in different tumors and can be used as tumor prognostic markers. This article reviews the role of SPINK1, 2, 4, 5, 6, 7, and 13 in different human cancer processes and helps to identify new cancer treatment targets.

show abstract

Glucuronic acid-conjugated smart cellulose nanocrystals as novel carrier for gemcitabine delivery

Ghadam

Faramarzi

Panahi

et al. 2023

Materials Chemistry and Physics

View full text Add to dashboard Cite

Enhancement of gemcitabine efficacy by K73-03 via epigenetically regulation of miR-421/SPINK1 in gemcitabine resistant pancreatic cancer cells

Cited by 6 publications

References 58 publications

Clinical role of miR-421 as a novel biomarker in diagnosis of gastric cancer patients

Clinical role of miR-421 as a novel biomarker in diagnosis of gastric cancer patients

SPINKs in Tumors: Potential Therapeutic Targets

Glucuronic acid-conjugated smart cellulose nanocrystals as novel carrier for gemcitabine delivery

Contact Info

Product

Resources

About